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Summary 
Mouse mammary tumor virus (MMTV) superantigens (vSAg) undergo proteolytic processing 
at residues that have been demonstrated in vitro to be recognition sites for the endoprotease fu- 
rin. To examine the role offurin in the presentation ofvSAg7 to T cells, the vSAg7 and class II 
MHC  IE  k genes were introduced into Chinese Hamster Ovary (CHO)  cells  (furin-positive) 
and into a furin-negative CHO variant (FD11). Both transfected cell lines efficiently presented 
peptide antigen and bacterial superantigens to T  cell hybridomas. However, while the furin- 
positive cells presented vSAg7 well, the furin-negative cells presented poorly. Transient trans- 
fection of the furin-negative cells with an expression plasmid containing thefurin gene restored 
the ability to present vSAg7 efficiently. The marginal presentation ofvSAg7 observed using the 
furin-negative transfectants was  eliminated after culture with the protease inhibitor leupeptin, 
suggesting that one or more endoproteases other than furin have a detectable but limited ca- 
pacity to proteolytically activate vSAg7. Biochemical analyses revealed that vSAg7 was largely 
unprocessed in the absence of furin. Thus, viral superantigens, unlike bacterial superantigens, 
require proteolytic processing to activate T cells. 
S 
uperantigens  interact with  class II  MHC  proteins and 
stimulate T  cells largely on the basis of their specificity 
for particular beta chain variable regions (Vf3) of the T  cell 
receptor  (1).  Unlike  conventional class II  MHC  peptide 
antigens, which are generated by proteolysis, superantigens 
are not thought to require proteolytic processing for pre- 
sentation to  T  cells.  Although  this  lack of processing ap- 
pears to be characteristic of  bacterial superantigens, MMTV 
superantigens (vSAg) have been detected on the surface of 
APC in a proteolytically processed form (2, 3). Proteolytic 
processing ofvSAg7 has been observed to occur at as many 
as three positions that correspond to the locations of basic 
amino acid motifs that are recognition sequences for a fam- 
ily of mammalian processing endoproteases known as con- 
vertases (4-6). Convertases typically cleave after sequences 
containing the  amino  acid  motif 1KXK/tL1K,  and  are  re- 
sponsible for the processing of cellular and viral precursor 
proteins  in  both  the  constitutive  and  regulated  secretory 
pathways (7-10). 
Phylogenetic comparison of vSAgs has  revealed a  high 
degree of conservation of the putative proteolytic process- 
ing sites  (11,  12),  and has suggested that processing is im- 
portant for activity. Mutagenesis of the convertase recogni- 
tion  motif at  position  168-171  in  vSAg7  blocked  the 
generation  of one processing product  (13).  The  mutated 
vSAg7 was not expressed at the cell surface, however, so it 
was  not determined whether the unprocessed vSAg could 
recognize T  cells had it been expressed on the cell surface. 
To clarify the role of proteolytic processing, vSAg7 pre- 
sentation was examined using APC that were deficient for 
the convertase furin. Furin is a candidate superantigen con- 
vertase  because  it  is  expressed  ubiquitously,  unlike  most 
convertases (14).  In addition, furin has been shown to pro- 
cess vSAg7 in vitro at two of the three candidate processing 
sites (13). To examine the role offurin in vSAg7 activation, 
the  vSAg7  and  class  II  IE  k genes  were  introduced  into 
CHO  cells,  and into a furin-negative variant,  FD11  (15). 
vSAg7 presentation was greatly reduced in the furin-nega- 
rive cell line, and the residual activity was eliminated by the 
addition  of the  protease inhibitor leupeptin.  Biochemical 
analyses revealed that vSAg7 was largely unprocessed in the 
absence  of furin.  Thus,  the  data  confirm that proteolytic 
processing is essential for vSAg7 presentation, and implicate 
furin as a candidate in vivo vSAg convertase. 
Materials  and Methods 
Biochemicals.  The moth cytochrome c (mcc 88-103) peptide 
was synthesized at the Wadsworth Laboratories. Staphylococcal  en- 
terotoxin A (SEA) was from Sigma Chemical Co. (St. Louis, MO). 
Plasmidsand Transfections.  The  vSAg7 expression  plasmid 
pSRc~vSAg7 was generated by cloning the EcoRI-BamHI frag- 
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versity) into the plasmid pSRocpuro (a gift of Dr. F. Denis, Insti- 
tut de Recherches Cliniques de Montr&l, Montr6al, QP, Canada). 
The IEkot chain expression plasmid pEXVE(x  has been described 
(16).  The  IEk[3 chain  expression plasmid phBATr-l-neo was  a 
gift of Dr. S. Hedrick (University of California, San Diego, CA). 
The  furin  expression plasmid pMT-PACE  has  been  described 
(17,  18). 
The CHO  and FD11  class II IE  k transfectants (CHIE;  FDtE) 
were generated using 10 I.Lg each of the IEc( and IE]3 expression 
plasmids,  and  15  ILl Lipofectamine  (Life  Technologies,  Grand 
Island,  NY) for 4 h in serum-free medium, followed by incuba- 
tion in complete medium overnight. The cells were plated at 1 ￿ 
104 cells/well in 24-well culture plates for 24 h before the addi- 
tion ofG418 (1 mg/ml; Life Technologies). Viable cells were an- 
alyzed and cloned by limiting dilution. The vSAg7 transfectants 
CHIE/S7  and FDIE/S7 were generated by secondary transfec- 
tion of CHIE and FDIE with pSRcxvSAg7,  followed by selection 
with  25  Izg/ml puromycin  (Sigma).  The  transient transfections 
were performed in an identical manner except that the cells were 
analyzed within 24 h. 
Antibodies.  The anti-vSAg antibodies VS7 and VS1, and the 
anti-IE antibody 14-4-4, have been described (2, 19). 
Flow Cytometry.  Flow  cytometry  was  performed  using  a 
FACScan|  flow cytometer (Becton Dickinson & Co., Mountain 
View, CA). Before analysis, cells were treated with 0.25% trypsin/1 
mM EDTA in HBSS, washed, and incubated in Complete Tu- 
mor Medium for 4  h  at 37~  to allow surface  re-expression of 
vSAg7. 
Cell Lines.  All cells were cultured in Complete Tumor Me- 
dium,  composed of Eagle's MEM  supplemented with  10  txM 
2-mercaptoethanol,  10%  fetal  calf serum,  10%  Mishell-Dutton 
Nutrient cocktail (20),  100  p~g/ml gentamycin, 100 U/ml peni- 
cillin G, and 200 Izg/ml streptomycin sulfate  (Sigma).  CHO cells 
and the furin-negative cell line FD11  have been described (15). 
The T  cell hybridomas Kmls13.11, K25-59.10,  5KC-73.8/51.6, 
and the vSAg7 expressing B cell lymphoma CH12/$7  have been 
described  (2,  21).  Other  T  cell hybridomas used  in  this  study 
were  generated from BALB/c T  cells after incubation for four 
days with  the  vSAg7  expressing cell line  CHIE/S7,  followed 
by  4 d  incubation  with  murine  IL-2  (625  U/ml).  The  T  cell 
blasts were  fused  to  the  thymoma BWer  ]3-  (22)  using stan- 
dard  methods,  and  cloned  by  limiting  dilution.  BWot-[3-, 
X63-1L-2,  and HT-2  cells were generously provided by Drs. J. 
Kappler  and  P.  Marrack  (Howard  Hughes  Medical  Institute, 
Denver, CO). 
T Cell Stimulation  Assays.  Assays were performed using 1 ￿ 
105 cells each ofa hybridoma and an APC. After 16-24 h super- 
natants were assayed for IL-2 using the indicator cell line HT-2 
(23). 24 h after the addition of the HT-2 cells [3H]thymidine was 
added (100  I.tCi/ml; Amersham Corp.,  Arlington Heights,  IL), 
the cultures were incubated for an additional 8-16 h, and thymi- 
dine incorporation was measured using a Betaplate Liquid Scintil- 
lation  Counter  (Wallac  Instruments,  Gaithersburg,  MD).  IL-2 
units were measured by comparison with murine IL-2 obtained 
from supernatants of the cell line X63-IL-2. Data were analyzed 
using the  computer program MKSET  (Dr. J.  Kappler, Howard 
Hughes Medical Institute, Denver, CO). 
Protein Chemistry.  Surface  radiolabeling, lysate  preparation, 
and  immunoprecipitations have  been  described previously  (2). 
Antigen was eluted from the Sepharose beads using 1 ml of 50 
mM diethylamine (pH 11.6),  lyophilized, and electrophoresed in 
8-20% gradient polyacrylamide gels. Gels were dried and autora- 
diographed for 5 d at -70~  using Hyperfilm ECL (Amersham) 
and an intensifying screen. 
Results 
vSAg7 Presentation by Furin-negative  CHO  Cells.  To  study 
the presentation of vSAg7 in the presence  and  absence of 
furin,  CHO  (furin-positive) and FD11  (furin-negative) cells 
were transfected with plasmids encoding the class II IE  k oe 
and [~ chains. IEk-positive transfectants underwent a second 
transfection with the vSAg7 expression plasmid pSP,  civSAg7, 
and puromycin-resistant cell lines were recovered. The  dou- 
bly-transfected lines were tested for their ability to stimulate 
the vSAg7-reactive hybridoma Kmls13.11  (V[36). 60% of the 
furin-positive transfectants (CHIE/S7;  n =  20),  but none  of 
the  furin-negative  transfectants  (FDIE/S7;  n  =  13),  pre- 
sented  vSAg7  (data  not  shown).  Several  cell  lines  were 
cloned by limiting dilution before further analysis. Surface 
expression of IE  k and vSAg7 on the transfectants was con- 
firmed using flow cytometry (Fig.  1).  The FDIE/S7 trans- 
fectants exhibited slightly reduced surface expression of IE  k, 
and  two-  to  fourfold  lower  levels  of vSAg7,  relative  to 
CHIE/S7  (Fig. 1 and data not shown). 
Both  the  furin-positive and  furin-negative transfectants 
were  capable APC,  as shown  by their ability to efficiently 
stimulate IL-2 production from a moth cytochrome c (mcc)- 
reactive T  cell hybridoma upon  addition of mcc  (88-103) 
peptide, and their ability to present SEA to a V[33-bearing 
T  cell hybridoma (Fig. 2 a). However, in contrast to the re- 
sults described above,  the data generated using the  cloned 
APCs indicated that weak presentation ofvSAg7 did occur in 
the absence of furin (Fig. 2  b). In general, responses to vSAg7 
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Figure  1.  Surface expression 
ofvSAg7 and IE  k. Adherent cells 
were  isolated after treatment 
with  trypsin/EDTA,  allowed to 
incubate in medium at 37~  for 
4 h to allow re-expression of the 
vSAg, and stained with biotiny- 
lated VS7  (vSAg7-specific;  solid 
lines), or biotinylated 14-4-4 (IE- 
specific; dashed line) followed by 
PE-coupled streptavidin, or with 
PE-coupled  streptavidin alone 
(dotted  lines), and  analyzed by 
flow cytometry.  (a)  The  furin- 
positive  transfectant CHIE/S7- 
16.4. The mean peak fluorescent 
intensities (MPFI) were 2.8 (PE 
control), 60.4 (VS7 positive cells), 
and  542  (14-4-4 positive cells). 
(b)  The  furin-negative transfec- 
tant  FDIE/S7-2.1.  MPFIs were 
6.5 (PE control), 24.7 (VS7 posi- 
tive cells), and 307 (14-4-4 posi- 
tive  cells). The  ordinate  repre- 
sents  the  relative  fluorescence 
(log scale) and  the  abscissa the 
relative cell number. 
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Figure 2.  Presentation  of antigen and superantigen by fnrm-negative 
cell lines. (a)  T  cell hybridomas were  incubated  with  furin-positive 
(CH1E, CHIE/S7)  and furin-negative (FDIE, FDIE/S7) APCs (1  ×  10  ~ 
each), with or without the addition of moth cytochrome c (88-103) pep- 
tide (mcc; 10  ~M),  or SEA (10 btg/ml). The T  cell hybridomas were 
5KC-73.8/51.6  (V[~3; moth cytochrome-specific) and K25-59.10 (V[33; 
SEA-reactive). CHIE and FDIE express IE  k in the absence ofvSAg7. As- 
say was for IL-2 production, as measured by assay for [3H]thymidine in- 
corporation by the IL-2-dependent cell line HT-2. Each histogram repre- 
sents  the  average determination  from  triplicate  cultures. Error  bars 
indicate the standard deviation of the mean, where greater than 10%. (b) 
The T cell hybridoma Kmlsl3.11 (V[36) was incubated with the indicated 
APC, and IL-2 production was measured, as in a. 
presented by the fiarin-negative cell lines were 5- to  10-fold 
lower than responses elicited by the furin-positive APC. 
Several other T  cell hybridomas were tested for responses 
to vSAg7 presented by the CHO  cells. Most available T  cell 
hybridomas, however, failed to detect vSAg7 on CHIE/S7. 
To  circumvent  this problem,  hybridomas were  generated 
that responded to vSAg7 presented by CHIE/S7. IL-2 pro- 
duction from a representative panel of hybridomas is shown 
in Fig. 3.  Although responses to  CH12/$7  and to CHIE/ 
$7  were  readily detected,  responses  to  FDIE/S7  were  ei- 
ther undetectable or very low (less than 6  U  IL-2/ml). Of 
the  27  new  hybridomas,  only  four  generated  detectable 
levels of IL-2. Thus,  the inefficiency in the presentation of 
vSAg7  by  the  furin-negative  ceils was  readily generalized 
upon examination of additional hybridomas. 
Reintroduction  of the Furin  Gene  Restored vSAg7 Presenta- 
tion.  To  determine  if the  defect  in  the  FDIE/S7  was 
indeed due to a lack of furin activity, thefim'~, gene was re- 
introduced into FDIE/S7 by transient transfection. Transient 
furin expression restored significant vSAg7 activity to FDIE/ 
hybridoma  Z~ 
Figure 3.  T cell bybridomas are deficient in their ability to recognize 
vSAg7 in the absence of furin. BALB/c T cells were cultured for 4 d with 
CHIE/S7, transferred to media containing IL-2 for 4 d, and fused to the 
thymoma BWci  13  . The T ceil hybridomas (Omls, numbered as shown) 
were tested for reactivity against the indicated APC. CH12/$7  is a 13 cell 
lymphoma vSAg7 transfectant (H-2k). 
$7, as detected by the response of five different hybridomas 
(Fig. 4).  Surface expression of vSAg7 was  not upregulated 
after reintroduction of furin (data not shown). The data in- 
dicated  that  the  defect  in  presentation  by  the  FDIE/S7 
transfectants  was  due  to  a  lack of furin  activity, and  sug- 
gested that proteolytic processing by furin played an impor- 
tant  role in vSAg7 presentation.  The  low levels of vSAg7 
activity observed in  the  furin-negative  antigen  presenting 
cells suggested either that vSAg7 retained some activity in 
the  absence  of  proteolytic  processing,  or  that  proteases 
other than furin also processed and activated vSAg7. 
Leupeptin  Inhibited  the  vSAg7  Activity  in  Furin-negative 
Cells.  To determine if leupeptin-sensitive proteases were 
responsible  for  the  activity  detected  in  FDIE/S7,  assays 
were performed in the presence or absence of the protease 
inhibitor leupeptin. Furin activity is unaffected by leupep- 
tin  (9). Leupeptin treatment eliminated the residual vSAg7 
activity detected by Orals42.6, but had no effect on presen- 
tation by CHIE/S7  (Fig. 5 a), or on SEA presentation (data 
not shown). The effect ofleupeptin was dose and time de- 
pendent (Fig. 5  b).  The failure to detect any activity under 
conditions  of optimal  leupeptin  treatment  indicated  that 
vSAg7 was not presented in the absence ofproteolytic pro- 
cessing.  The  data  strongly suggested  that  proteolytic pro- 
cessing  was  necessary  for  vSAg7  presentation  to  T  cells. 
The  identity of the leupeptin-sensitive protease(s) has  not 
been determined. 
Minimal Processing of vSAg7 in the Absence of Fusn.  To de- 
ternfine if the  antigen presentation  deficiency in  FDIE/S7 
was due to a failure to process vSAg7, a biochemical analy- 
sis was performed. CHIE/S7  and  FDIE/S7 cells were sur- 
face  radiolabeled with  125Iodine,  and  vSAg7  was  precipi- 
tated using the antibody VS1, which recognizes the amino 
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Figure  4.  Presentation of vSAg7 is restored by reintroduction of the 
fitrin gene. FDIE/S7 was transfected with  10 p,g of the furin expression 
plasmid pMT-PACE  (cross-hatched histograms), or mock-transfected (open 
histograms) 24 h before addition of hybridoma cells. T  cell hybridomas 
(numbered as in Fig. 3, followed by the clone designation) were tested for 
responses to the indicated APC. Each histogram represents the average 
determination  from  triplicate cultures. The  standard deviation  of the 
mean was less than 10% for all samples. 
terminus of all vSAgs. In previous experiments, the radiola- 
beled carboxy-terminal processing product was bound non- 
covalently to  the amino terminus  (3)  and was precipitated 
by  VS1.  The  previously  characterized  18.5-kD  carboxy- 
terminal processing product was  readily precipitated from 
lysates of CHIE/S7,  but was  nearly undetectable in lysates 
of FDIE/S7  (Fig. 6).  The  majority of the vSAg7 detected 
in FDIE/S7 nfigrated with a mobility in the range of 105- 
120  kD,  and  represented  the  unprocessed  vSAg7.  Other 
vSAg7  proteins  detected  on  CHIE/S7  represent  amino- 
terminal  proteolytic  cleavage  products,  or  perhaps  some 
unprocessed vSAg7 (Fig. 6). 
Discussion 
On the basis of the data presented,  it can be concluded 
that proteolytic processing is necessary for activation ofT cells 
by vSAg7. In the absence of furin most T  cell hybridomas 
were  unable  to  respond  to  vSAg7,  and  the  low  level re- 
sponses  detected with  some  hybridomas were  completely 
inhibited by addition of leupeptin.  Reintroduction of the 
furin  gene into the furin-negative cells rescued vSAg7 pre- 
sentation,  indicating that  the  failure of the  furin-negative 
cells to present vSAg7 was indeed due to a loss of furin ac- 
tivity. It has not been formally demonstrated that rescue of 
vSAg7  presentation  was  accompanied  by  restored  pro- 
teolytic processing. However,  furin is a well-characterized 
protein  convertase,  and  has been  demonstrated  to  process 
vSAg7 in vitro, so the most likely explanation is that rein- 
troduction of thefurin  gene restored vSAg activity through 
proteolytic processing. Biochemical analyses revealed a lack 
of vSAg7  processing  in  the  furin-negative  cells,  because 
• 
I00. 
I0' 
0.1 
0  1 
b 
i 
leupeptin  eonc.  (mM) 
Figure 5.  Treatment of furm- 
negative  cells w'ith leupeptiu 
eliminated  vSAg7 activity.  (a) 
APC  were  untreated,  or  incu- 
bated with leupeptin for 8 h be- 
fore and subsequent to the addi- 
tion  of the  T  cell hybridoma 
Orals42.6.  Filled  histograms: 
CHIE/S7;  open  histograms: 
FDIE/S7. The data represent the 
mean and standard deviation of 
three  determinations.  (b)  Dose 
response.  Antigen  presenting 
cells were treated without (dosed 
symbols),  or with leupeptin (open 
symbols) at the indicated concen- 
trations, for 24 h (triangles), 8  h 
(circles), and 4 h  (squares) before 
and after the  addition of the  T 
cell hybridoma Orals 42.6. Each 
data point represents a single de- 
temfination. The transfectant cell 
lines  were  routinely  passaged 
with  trypsin/EDTA.  However, 
the vSAg7 activity detected with 
FDIE/S7  was not an artefact of 
trypsinization, because the  SAg 
activity could be detected when 
the  cells were  disrupted  using 
only EDTA, or when disruption 
was  performed  mechanically 
(data not shown). 
nearly  all  of the  detectable  vSAg7  migrated  with  a  high 
electrophoretic mobility (>105  kD).  However,  because a 
convertase recognition sequence is found in vSAg7 at posi- 
tion  68-71,  vSAg7  processed  only at  this  amino-terminal 
position would not have  been  detected after immunopre- 
cipitation with  VS1.  The  data  are  nevertheless  consistent 
with the  simplest explanation, that  only very limited pro- 
cessing occurred in the absence of furin. 
In a previous study it was also concluded that proteolytic 
processing was required for vSAg activity (13). Analysis of a 
nmtant  form  of vSAg7,  in  which  the  convertase  recogni- 
tion sequence at position 168-171  was destroyed, revealed 
that the mutant protein was not transported to the cell sur- 
face in the B  cell lymphoma CH12.1.  In contrast, the sur- 
face expression of unprocessed vSAg7  observed in  the fu- 
rin-negative cells indicated that proteolytic processing was 
not required for surface expression, nor did reintroduction 
of furin upregulate vSAg7 surface expression. It is possible 
that the defect in intracellular transport observed in studies 
of the mutated vSAg7 was due to the amino acid substitu- 
tions,  which  may have  interfered with surface  expression. 
Alternatively,  the  requirements  for  surface  expression  of 
vSAg7 may differ between B  cells and CHO  cells. 
Although the requirement for proteolytic processing has 
been demonstrated here for vSAg7, it is likely that this re- 
quirement exists for all viral superantigens. Most vSAg con- 
tain  consensus  convertase  recognition  sequences  at  posi- 
tions 68-71,  168-171,  and 190-194  (numbering as in vSAg7). 
However,  it  is  not  known  at  which  positions processing 
nmst take place for vSAg activation to occur. Not all vSAg 
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unprocessed  in  furin-negative 
cells. Furin-positive (CHIE/S7, 
lanes I and 2) and furin-negative 
(FDIE/S7,  lanes 3 and  4)  cells 
(5 X  107) were surface radiola- 
beled with  0.5  mCi  12Slodine, 
lysed  in  PB$  containing  1% 
NP-40  and protease inhibitors, 
and  vSAg7 was  precipitated 
with  the  anti-vSAg  antibody 
VS1. -/+  refers to the absence 
or presence  of  VSl-specific com- 
petitor peptide  during the pre- 
cipitation. Solid arrow  indicates 
the carboxy-terminal  proteolytic 
cleavage product  (lane 0; open 
arrow indicates the presumptive 
unprocessed vSAg7 (lane 4). 
proteins in an individual cell undergo processing at all pos- 
sible recognition sites. Thus,  processing may generate sev- 
eral forms  of vSAg,  and  the  differentially processed vSAg 
may  function  as  superantigens,  or  perhaps  perform  yet 
other roles in viral pathogenesis (24). 
The  data also suggest a  role in vivo for furin as a  vSAg 
convertase.  This  does  not  suggest,  however,  that  other 
convertases  might  not  also  process  vSAg.  For  example, 
PACE4,  and the  newly discovered PC7  (25),  are also ex- 
pressed in cells that are known to express vSAg. 
The  biochemical  data  revealed  that  in  the  absence  of 
proteolytic processing, vSAg7 migrated in SDS polyacryla- 
mide  gels  with  a  mobility of 105-120  kD.  The  apparent 
size is even greater than that detected previously in B  cells, 
where vSAg7 was observed to migrate at ,'-~82 kD  (3), and 
may be due to cell type differences. The size heterogeneity 
of vSAg7 has been shown  to be due at least in part to the 
addition  of N-linked  carbohydrate.  The  core  molecular 
weight  of vSAg7  is  37  kD,  so  posttranslational modifica- 
tions may contribute as much  as 80 kD to the mature pro- 
tein. The high levels of carbohydrate may be important for 
folding or intraceUular trafficking, because mutant vSAgs that 
carried a reduced amount of N-linked oligosaccharide exhib- 
ited impaired surface expression (McMahon, C., L. Bogatzki, 
and A. Pullen, manuscript submitted for publication). 
Why  do  vSAgs require  processing for  activation?  Pro- 
teolytic processing is generally used by cells and by patho- 
gens to regulate biological activity. For example, processing 
of influenza hemagglutinin reveals a peptide that binds to a 
cell surface receptor and facilitates virus fusion (26).  Previ- 
ous experiments have suggested that processed vSAg7 may 
have  a  higher affinity for class II proteins than  the  unpro- 
cessed vSAg (3), so proteolytic processing may in a  similar 
manner  reveal  a  binding  site  on  vSAg for  class  II  MHC 
proteins. 
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